Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Pseudomyogenic hemangioendothelioma Indication Strategy Report 2026: FOSB, Trials and Deals
30 July 2026
2026 Pseudomyogenic hemangioendothelioma indication strategy covering epidemiology, FOSB biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Kaposiform hemangioendothelioma Indication Strategy Report 2026: mTOR, Trials and Deals
30 July 2026
2026 Kaposiform hemangioendothelioma indication strategy covering epidemiology, mTOR biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Angiosarcoma of the scalp Indication Strategy Report 2026: VEGFR, Trials and Deals
30 July 2026
2026 Angiosarcoma of the scalp indication strategy covering epidemiology, VEGFR biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Epithelioid hemangioendothelioma Indication Strategy Report 2026: YAP1-TFE3, Trials and Deals
30 July 2026
2026 Epithelioid hemangioendothelioma indication strategy covering epidemiology, YAP1-TFE3 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
PEComa Indication Strategy Report 2026: mTOR, Trials and Deals
30 July 2026
2026 PEComa indication strategy covering epidemiology, mTOR biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Malignant glomus tumor Indication Strategy Report 2026: NOTCH, Trials and Deals
30 July 2026
2026 Malignant glomus tumor indication strategy covering epidemiology, NOTCH biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Sclerosing epithelioid fibrosarcoma Indication Strategy Report 2026: MUC4, Trials and Deals
30 July 2026
2026 Sclerosing epithelioid fibrosarcoma indication strategy covering epidemiology, MUC4 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Low-grade fibromyxoid sarcoma Indication Strategy Report 2026: MUC4, Trials and Deals
30 July 2026
2026 Low-grade fibromyxoid sarcoma indication strategy covering epidemiology, MUC4 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Ewing-like sarcoma Indication Strategy Report 2026: CIC-DUX4, Trials and Deals
30 July 2026
2026 Ewing-like sarcoma indication strategy covering epidemiology, CIC-DUX4 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Undifferentiated round cell sarcoma Indication Strategy Report 2026: NTRK, Trials and Deals
30 July 2026
2026 Undifferentiated round cell sarcoma indication strategy covering epidemiology, NTRK biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Extraskeletal myxoid chondrosarcoma Indication Strategy Report 2026: NR4A3, Trials and Deals
30 July 2026
2026 Extraskeletal myxoid chondrosarcoma indication strategy covering epidemiology, NR4A3 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Microcystic adnexal carcinoma Indication Strategy Report 2026: Hedgehog, Trials and Deals
30 July 2026
2026 Microcystic adnexal carcinoma indication strategy covering epidemiology, Hedgehog biology, active trials, transactions, unmet need, competition and market…